Adding Ensifentrine to Tiotropium Therapy Improves Lung Function in COPD, Top-line Results Show

Adding Ensifentrine to Tiotropium Therapy Improves Lung Function in COPD, Top-line Results Show
Verona Pharma announced positive top-line results on the use of nebulized ensifentrine as an add-on to tiotropium (Spiriva Respimat) in people with moderate-to-severe chronic obstructive pulmonary disease (COPD). The results come from a Phase 2b clinical trial (NCT03937479), which showed that ensifentrine — when added as a nebulized suspension to inhaled tiotropium — significantly improved the participants' lung function and quality of life. Ensifentrine, previously known as RPL554, acts as both a bronchodilator to widen the airways and as an anti-inflammatory agent. It works by inhibiting the phosphodiesterase 3 and 4 (PDE3 and PDE4) enzymes linked to COPD development. Tiotropium is a long-acting anti-muscarinic (LAMA) bronchodilator commonly used to treat COPD. It is marketed as Spiriva Respimat by Boehringer Ingelheim. The Phase 2b trial, launched in 2019, enrolled 416 people with moderate-to-severe COPD who received either placebo or nebulized ensifentrine as an add-on to tiotropium treatment. The treatment was
Subscribe or log in to read the rest of this content.